- Illumina | Sequencing and array solutions to fuel genomic discoveries
Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics
- Has Illumina’s Recent Rebound Created a Long Term Opportunity in 2025?
If you are looking at Illumina and wondering whether today’s price really reflects its long term potential, you are not alone; this stock has gone from market darling to question mark and back
- Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Illumina (ILMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy) This rating change essentially reflects an upward trend in earnings estimates -- one
- About Us | A global leader in genomics - Illumina
We are Illumina We are a global genomics and human health leader innovating the future of precision health We develop DNA sequencing and array-based life sciences technologies to enable boundless research discovery and personalized health
- Invesco Ltd. Buys 444,543 Shares of Illumina, Inc. $ILMN - MarketBeat
Invesco Ltd lifted its stake in Illumina, Inc (NASDAQ:ILMN - Free Report) by 48 9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission The institutional investor owned 1,353,077 shares of the life sciences company's stock after acquiring an additional 444,543 shares during the period Invesco Ltd owned 0 88% of Illumina worth
- Illumina, Other Genomics Fims Ramp Up Data Offerings for Pharma, With . . .
NEW YORK – Illumina has long been content to supply as many sequencing reagents as the pharmaceutical industry could handle, but now the firm is willing to offer a more refined product: data Under plans for its new BioInsight business unit, announced in October, Illumina is willing to shoulder the burden of certain sequencing-intensive projects of interest to pharma, such as single-cell
- Illumina, Inc. (ILMN) Up 4. 9% - Weiss Ratings
About Illumina, Inc Illumina, Inc is a global leader in genomics, providing sequencing and array-based technologies that power research, clinical and applied markets across the life sciences
- Illumina launches China production site in Minhang
Illumina, a DNA sequencing and array-based technologies provider, has put into operation its first China manufacturing site in Shanghai, further indicating that multinationals see the city as an attractive destination for further investment
|